PRESS CENTER
新聞中心
News
-
2025/05/26Mycenax, Kidswell Bio and Chiome Bioscience Enter into Master Service Agreement for Development of New Biosimilar Drugs
-
2025/05/22Mycenax Partners to Establish Japan's Domestic Biosimilar Manufacturing Facilities
-
2025/05/19Mycenax Launches Commercial Manufacturing for Our First Internationally Approved Biopharmaceutical
-
2025/03/07Mycenax and Sartorius Join Forces to Enhance Biopharmaceutical Manufacturing Solutions
-
2024/11/28Mycenax and Apexcella collaborate to Advance Commercialization of Allogeneic Natural Killer Cell Therapies to Benefiting More Patients
-
2024/10/17Opening Ceremony of Mycenax's New Automated Fill-Finish Line
-
2024/06/26MYCENAX and CHITOSE Join Forces to Forge a New Era of Cell Line Development
-
2024/01/24Merck Signs MoU with Mycenax Biotech to Drive Innovation in Bioprocessing Technology
-
2023/06/15Mycenax Biotech has signed an MOU with StemCyte to strengthen its one-stop service chain for allogeneic cell therapy
-
2023/06/01Construction Commencement of Mycenax Biotech's Cell Therapy Pilot Plant
- 1
- 2
- 3